– USA, CT – Simcha Therapeutics, a biotechnology company developing cytokine-based cancer immunotherapies, today announced the closing of a $40 million Series B financing led by SR One Capital Management alongside new investors including BVF Partners, Samsara BioCapital, Rock Springs Capital, ArrowMark Partners, and Logos Capital.
Concurrent with the financing, Dr. Simeon George (M.D.), CEO of SR One Capital Management, has joined the Board of Directors.
“We intend to become a leader in creating the next-generation of cytokine immunotherapies, and this investment from a phenomenal group of blue-chip firms represents a major endorsement of our progress to date and future potential,” said Dr. Aaron Ring, Simcha Therapeutics Founder and Assistant Professor of Immunobiology at the Yale School of Medicine. “The Series B comes at a pivotal time in Simcha’s development as we have transitioned to a clinical-stage company and continue to build our leadership team.”
Dr. Simeon George added, “Simcha is developing highly innovative drugs that are completely unlike any other immunotherapeutic agent in development. We are proud to support the company in advancing this extremely promising agent for cancer patients.”
About Simcha Therapeutics
Simcha Therapeutics uses directed evolution to engineer novel cytokines designed to unlock the precision and power of the immune system. Simcha’s lead program, ST-067, is a designer IL-18 cytokine that has shown potent antitumor effects in animal models, both as a monotherapy and when combined with anti-PD-1 checkpoint inhibitors, as described in Nature in June 2020. A Phase 1 clinical trial commenced in the second half of 2021. Simcha was founded in 2018 by Aaron Ring, MD, Ph.D., Assistant Professor of Immunobiology at the Yale School of Medicine.
For more information: https://www.simchatx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
